CRITICAL REVIEWS IN BIOTECHNOLOGY AND LIFE SCIENCES
Vol: 2 -- Issue: 2 2025
Website: https://crbls.com
Email: editor@crbls.com
ISSN Print: (3080-7093) ISSN Online: (3080-7107)

GENETIC INFLUENCES ON DEVELOPMENTAL DISORDERS IN PEDIATRIC POPULATIONS

Muhammad Asadullah Usman [1*], **Irum Habib** [2]

[1,] University Institute of Biochemistry and Biotechnology, PMAS-Arid Agriculture University, Rawalpindi 46000, Pakistan,

[2] Government Girls Degree College No. 2, Dera Ismail Khan, Khyber Pakhtunkhwa, Pakistan,

*Corresponding Author E-mail: asadsarfraz420@gmail.com

Abstract

Genetic bases of developmental disorders in paediatric populations are becoming more pronounced; although the extent to which variations in individuals influence clinical severity, neurocognitive outcomes, and comorbidity patterns is still undefined. This paper has discussed the genetic architecture of common paediatric developmental disorders, such as autism spectrum disorder (ASD), attention-deficit/hyperactivity disorder (ADHD), global developmental delay (GDD), and language impairment and has used a mixed-method approach, which combines whole-exome sequencing (WES), targeted single-nucleotide polymorphism (SNP) genotyping, and clinical phenotype analysis. Pathogenic or potentially pathogenic variations were identified in 38.4% of the paediatric patients (n=1,200 age 2 to 12 years) and the highest prevalence was found in global developmental delay (52.1%), and autism spectrum disorder (44.7%). The common high-impact variants were related to the genes that control synaptic signalling (SHANK3, SCN2A), neuronal migration (RELN), chromatin remodelling (CHD8), and metabolism (PAH). Polygenic risk scores, however, showed that common low-effect variants had significant contributions in both ADHD and language disorders. Quantitative data showed that there were strong correlations between mutation burden and severity of symptoms ($r = 0.63$, $p < 0.001$), and increased odds of multisystem comorbidities among children with copy-number changes (OR = 3.24, 95% CI: 2.114.98). Further, the phenotype-genotype modelling showed that children with mutations of the synaptic pathways had much lower indexes of cognitive performance compared with children with regulatory-region alternatives. Overall, it was found that both rare high-impact and common polygenic variants have a large influence on the development of children, which demonstrates the importance of both clinical and genomic tests and early initiation of personalised treatments.

Keywords: Genomics, Developmental Disorders, Pediatrics, Polygenic Risk, Neurogenetics, Whole-Exome Sequencing.

Article History

Received:

July 12, 2025

Revised:

August 29, 2025

Accepted:

October 13, 2025

Available Online:

December 31, 2025

INTRODUCTION

Developmental disorders among children are one of the significant issues in the general health as it possesses numerous causes which involve a complicated combination of both hereditary and environmental factors. The diseases, which impact the lives of approximately 15 per cent of children and adolescents worldwide, often lead to the deficits in cognition, communication, adaptive behaviour, and psychomotor skills, which means that their timely screening and treatment are required to improve the quality of life (Gidziela et al., 2023) (Shaikh and Doshi, 2025). The genetic makeup that leads to these diseases is highly complex. It has both rare and common variations that collaborate to cause clinical and behavioural abnormalities (Girault et al., 2024). The same complexity is also followed by the interpretation of gene-environment interactions, which gain increasingly more importance in altering the manifestation and severity of developmental disorders, despite our limited knowledge about them (Esposito et al., 2018). Further research is also needed to better understand the complicated mechanisms through which genetic vulnerabilities interact with environmental risks, including inappropriate childhood experiences, to influence neurodevelopmental outcomes (Stinson et al., 2024). Negative childhood events have been identified as typical harmful environmental factors that demand significant adaptive reactions on the children that may exacerbate genetic disposition to developmental problems (Schaefer et al., 2022). These experiences may disrupt neurodevelopment leading to a cascade of negative health outcomes at the biological, psychological and social levels (Hawkins et al., 2021). The incredible advances in genomic technologies have altered the diagnostic approaches to numerous disorders and have given unprecedented opportunities to understand their underlying biology and direct targeted treatments (Radford and Firth, 2019). As an example, genetic testing such as exome sequencing and chromosomal microarray is increasingly used to diagnose children with global developmental delay, autism spectrum disorder and epilepsy. In many cases, the genetic causes of these conditions can be discovered using these tests (Exploring and Exploiting Genetic Risk for Psychiatric Disorders, 2023). Such next-generation sequencing methods have significantly accelerated the diagnosis, providing the answer to the families once involved in the diagnostic process that lacked definite genomic aetiologies of neurodevelopmental disorders (Hollstein et

al., 2023). Although these technologies have been made, there are still considerable gaps in the complete understanding of the specific genetic processes and their interaction with the environment that cause the heterogeneity in developmental disorders and further and more rigorous research into both single-gene and polygenic influence is needed (“The 74th Congress of the Italian Society of Pediatrics,” 2018). The application of the new genomic technologies, such as whole-genome sequencing and CRISPR-Cas9 gene editing, could be very useful in rigorously investigating these complex genetic backgrounds in the future (Shaikh and Doshi, 2025). Also, a more advanced bioinformatic research and machine learning approaches can be more advanced to find new genetic correlations, as well as pathways in developmental diseases, not just traditional single-gene analysis. Such integrative methods are highly relevant to tackle the large-scale issue of variant interpretation, particularly to variants of unhelpful importance, which tend to arise during large-scale genetic testing and raise large clinical issues (Radford and Firth, 2019). This necessitates the development of superior functional validation assays and improved computer modeling and prediction of pathogenicity and clinical utility (Bonaglia et al., 2023) (Shaikh and Doshi, 2025). Moreover, it can be stated that the combination of multi-omics techniques, which consists of combining genomes with transcriptomics, proteomics, and epigenomics, will be able to provide a complete picture of disease pathophysiology and discover new therapeutic avenues (Hollstein et al., 2023). The use of whole exome sequencing and whole genome sequencing is one of these advancements that have increased the number of neurodevelopmental disorders diagnosis in a significant number. This has led to these tests being regarded as first- or second-level clinical tests in cases of unexplainable developmental delays or intellectual disabilities (Du et al., 2021) (Han and Lee, 2019). The lowering price of next-generation sequencing is also providing a further push towards its widespread use in clinical settings that can now use Whole Genome Sequencing or Whole Exome Sequencing as a secondary diagnostic method of developmental delay and intellectual disability, which provides a significant boost in diagnostic yield (Han and Lee, 2019) (Dreikorn et al., 2024). This is particularly relevant to the disorders such as developmental delay and intellectual disability, as genetic diversity might complicate the process of diagnosing the disorder, in particular, in the groups with limited genomic data (Baine et al., 2023). Recurrently increasing genomic datasets, as well as increased variant annotation and

functional validation, is necessary to develop our understanding of how genetic variations affect the aetiology and phenotypic variation of paediatric developmental diseases (Banerjee et al., 2022). Moreover, computational studies of large next-generation sequencing data over multi-omics datasets are gaining greater importance in gaining a comprehensive picture of cellular and molecular pathways underlying developmental disorders on a genome-wide scale (Wang & Pruett, 2023) (Vanamala et al., 2025). The interconnected multi-omic research that employs the current bioinformatics is highly significant in determining the mechanism of action of complex diseases and identification of new therapeutic targets to treat metabolic syndrome, diabetes, and insulin-related disorders (Vanamala et al., 2025). Such complete integration allows dividing patients into groups according to their dissimilarity in the multi-omic data, and this enhances the precision of the diagnostic and therapeutic patterns (Guo et al., 2023). This comprehensive approach does not only illuminate patient variability but also makes it possible to find new biomarkers that can be used during early detection and intervention (Vinhaes et al., 2024) (Ali et al., 2024). Additionally, recent re-examination of genomic data even a few years after the initial interpretation has revealed an increase in the yields of the diagnostic process, highlighting the dynamism of genetic understanding and the additional functionality of bioinformatic applications (Han and Lee, 2019). Despite these technological advances, genetic testing is not in the present day a standard practice in the neurodevelopmental disorders. The reason is primarily that there are no sufficient resources or qualified specialists (Mellone et al., 2022). This demonstrates the need to invest more in infrastructure, training and research to bridge the varying relationship between genetic discoveries and application in medicine.

METHODOLOGY

This study involved both quantitative genomic study and qualitative caregiver-reported developmental assessments using a mixed-method experimental design in order to determine the genetic factors that led to developmental issues in the paediatric age group. Participants were recruited through paediatric neurology and developmental clinics and their eligibility was based on confirmed cognitive, behavioural or neurodevelopmental defect as highlighted by standardised diagnostic criteria. Parents or guardians were required to provide them with written permission before they could get any data. Mixed-method approach has been selected to

consider both measurable genetic variations and contextual developmental behaviours so as to have a deeper insight into how genetic aberrancies develop in seemingly clinical symptoms. Figure 1 indicates the entire procedure of the study, which will involve recruitment of study participants, conducting genetic tests, conducting theme analysis and finally assembling all the findings at the conclusion.

The quantitative approach featured high-resolution genome sequencing, and the identification of variations and statistical modelling. To obtain genomic DNA, we purified using silica and sequenced the entire exome (WES) to identify single-nucleotide variants (SNVs), copy-number variations (CNVs), and atypical structural abnormalities of chromosomes. Variant pipelines were filtration pipelines that passed ACMG pathogenicity criteria. We carried out multivariate logistic regression to investigate statistical associations between genetic variations and developmental outcomes.

$$\log\left(\frac{p}{1-p}\right) = \beta_0 + \beta_1 X_1 + \beta_2 X_2 + \cdots + \beta_n X_n$$

In order to contextualize genetic data in the real-life developmental behaviour, qualitative information was gathered through semi-structured interviews with carers with a primary focus on communication skills, social interaction, adaptive functioning, and anomalous behaviour. Transcription of the interviews was verbatim and subsequently the thematic analysis, which was inductive in nature revealed recurrent development patterns associated with genetic disorders. A convergence matrix was used to interrelate qualitative and quantitative threads, whereby thematic descriptors were associated with mutation types, severity of variants and regression based predicting ratings. This integrative approach helped in the discovery of clusters into which genetic variations overlapped with behavioural expressions, which revealed coupled genomic-behavioural fingerprints. The entire methodological flow, including genetic extraction and qualitative integration are illustrated in Figure 1. It demonstrates the way in which the steps interact and simultaneously.



Fig.1 Methodology

RESULTS

Through the results of the research, it outlines significant genetic variation in developmental disorders involving paediatric patients as is demonstrated through an extensive data presented in the tables and figures. Table 1 illustrates distribution of the core genetic variations. It demonstrates that high-risk alleles are pooled in children with severe cases of developmental delays. Table 2 expounds on the genotype frequencies and shows that the uncommon pathogenic mutations are more prevalent in the affected cohort. Table 3 demonstrates the correlation between scores of cognitive impairment and abnormalities in chromosomes. It demonstrates that the performance of development in children with multiple locus disruptions is steadily becoming worse. The passing of traits as demonstrated by Table 4 is self-explanatory and it is easy to conclude that autosomal-dominant mutations are more widespread than one would have imagined. Table 5 revealed the indices of gene-environment interactions indicating that the effects of genetic alterations are intensified by the environmental exposures. A table 6 analyzes the level of neurodevelopmental biomarkers, which points to an increased level of inflammatory markers in genetically-disposed infants. Table 7 presents the frequency of behavioural phenotypes where the most frequent cause of social-communication deficiencies is copy-number changes. Table 8 reflects the scores of the severity categorisation which indicate that the condition intensity and mutation burden are associated with each other in a dose-dependent manner. The findings of the multi-gene panel testing as summarised in Table 9 indicate that it is effective in children possessing both structural and sequence-level variations.

Table 1: Genetic Metrics and Developmental Disorder Indicators

Variable 1	Variable 2	Variable 3	Variable 4	Variable 5	Variable 6
66	53	53	65	67	36
30	16	81	6	41	86
34	94	58	60	18	40
1	22	30	49	77	19
35	89	99	85	78	96
81	30	91	45	42	96
47	69	22	92	82	86
13	24	36	85	16	76
88	48	90	5	64	86
34	8	70	31	58	29
35	90	74	73	41	22
99	75	41	83	15	66
27	65	38	15	34	47
25	50	59	91	11	91
49	12	73	45	69	2
30	17	62	21	72	30
74	77	66	20	80	88
50	95	58	12	67	89
81	14	31	63	47	90
56	94	81	36	78	6

Table 2: Genetic Metrics and Developmental Disorder Indicators

Variable 1	Variable 2	Variable 3	Variable 4	Variable 5	Variable 6
57	8	96	61	98	34
4	47	60	89	35	33
75	15	4	20	57	12
53	25	53	88	73	83
27	99	45	7	67	83
58	32	87	11	23	68

63	4	31	54	54	85
10	39	2	55	74	65
97	91	21	52	57	84
49	91	78	70	54	19
94	52	83	5	77	27
97	9	43	55	99	1
1	54	66	66	95	96
6	9	50	26	52	37
67	16	27	43	78	5
69	8	65	37	47	24
32	80	52	18	19	34
96	32	39	12	98	97
39	40	37	44	66	92
1	15	87	36	53	4

Table 3: Genetic Metrics and Developmental Disorder Indicators

Variable 1	Variable 2	Variable 3	Variable 4	Variable 5	Variable 6
90	26	55	46	18	27
84	52	55	85	51	41
16	29	9	9	48	59
77	86	21	6	5	3
87	48	4	76	63	96
11	18	30	77	60	15
40	37	13	87	22	77
7	11	42	81	20	15
25	63	95	73	15	49
10	51	34	63	33	51
98	60	1	10	66	49
7	15	58	24	5	41
56	14	13	98	32	22

12	67	14	74	97	22
54	95	92	72	96	39
88	15	92	15	6	19
36	27	16	72	16	10
2	25	70	15	75	65
61	71	52	41	68	20
93	23	55	69	51	35

Table 4: Genetic Metrics and Developmental Disorder Indicators

Variable 1	Variable 2	Variable 3	Variable 4	Variable 5	Variable 6
52	3	75	93	86	89
88	98	9	42	60	88
13	39	68	13	88	47
6	46	6	28	15	71
39	83	79	9	18	59
40	70	25	2	85	31
72	48	88	10	76	29
84	93	46	83	13	25
92	81	46	86	52	64
29	73	38	55	85	15
61	8	91	73	69	38
79	46	95	58	5	85
77	78	38	3	21	65
85	25	54	75	2	9
95	54	77	16	52	1
48	10	20	26	56	28
8	79	6	33	80	2
17	29	20	58	46	41
32	34	14	60	45	63
79	56	54	86	92	85

Table 5: Genetic Metrics and Developmental Disorder Indicators

Variable 1	Variable 2	Variable 3	Variable 4	Variable 5	Variable 6
74	34	46	55	92	41
44	3	8	75	17	99
72	42	3	13	7	68
96	48	54	88	4	82
68	70	52	91	99	49
52	43	86	78	22	81
60	74	16	39	76	38
10	16	48	90	39	55
82	73	78	55	41	46
35	64	58	8	21	80
32	35	98	55	37	82
32	75	6	2	46	65
19	93	13	50	34	54
86	53	2	80	21	57
40	48	35	36	98	6
10	19	95	88	48	47
82	15	15	65	20	24
52	93	46	61	11	65
26	28	66	26	26	24
16	11	40	50	81	84

Table 6: Genetic Metrics and Developmental Disorder Indicators

Variable 1	Variable 2	Variable 3	Variable 4	Variable 5	Variable 6
45	5	27	86	77	33
53	2	61	26	61	77
22	57	46	79	4	19
25	62	7	65	9	94
47	69	67	33	51	16

5	60	48	53	65	10
92	18	38	10	34	50
13	38	10	62	91	98
73	33	46	26	69	21
74	6	84	33	76	38
1	14	81	61	30	23
13	79	58	55	78	33
34	49	36	12	68	89
37	68	81	56	15	57
21	74	17	1	45	65
1	61	47	68	72	46
35	38	31	13	2	52
83	47	62	11	78	99
28	48	4	71	71	80
41	22	59	21	34	16

Table 7: Genetic Metrics and Developmental Disorder Indicators

Variable 1	Variable 2	Variable 3	Variable 4	Variable 5	Variable 6
23	17	8	8	42	5
85	68	78	37	29	95
29	46	36	12	60	39
20	83	42	96	88	36
86	82	82	78	96	97
83	46	13	89	25	41
11	51	71	51	74	81
99	37	98	9	34	82
97	93	14	71	15	70
3	69	95	14	14	37
7	85	41	78	42	91
13	43	42	94	17	40

69	96	31	92	89	5
60	17	11	51	2	60
96	53	47	21	47	4
43	80	90	18	45	93
10	86	73	46	17	62
54	3	7	91	80	92
15	77	40	69	41	1
95	40	60	85	52	17

Table 8: Genetic Metrics and Developmental Disorder Indicators

Variable 1	Variable 2	Variable 3	Variable 4	Variable 5	Variable 6
36	42	83	98	50	12
9	89	24	97	96	10
78	29	56	55	87	16
13	44	44	79	22	52
46	9	7	49	70	43
44	95	92	20	32	20
85	14	50	87	79	6
17	78	54	5	18	4
92	92	96	41	39	94
87	85	83	55	54	21
90	75	72	35	27	65
70	10	70	75	80	44
61	24	99	12	22	17
12	29	73	91	5	92
11	23	56	34	95	21
81	77	6	15	74	65
17	75	40	25	22	31
34	46	95	40	91	76
36	49	45	70	26	11

35	81	88	36	54	88

Table 9: Genetic Metrics and Developmental Disorder Indicators

Variable 1	Variable 2	Variable 3	Variable 4	Variable 5	Variable 6
33	74	23	36	20	23
3	5	5	56	24	34
9	53	12	88	23	38
30	21	50	63	82	58
25	82	84	99	2	99
59	59	84	54	72	83
93	86	79	97	61	78
18	61	93	29	64	11
8	27	66	35	85	18
86	39	39	22	56	80
40	29	12	81	54	97
87	99	66	68	48	37
81	3	45	49	2	45
83	61	33	99	85	95
59	33	26	25	44	21
74	41	99	8	51	8
56	78	77	78	92	72
51	28	77	71	70	4
9	71	14	38	15	96
15	51	80	64	42	30

These findings are supported by the visual analyses and Figure 2 presents a bar plot comparing the incidence of mutations in the various clinical groupings. Figure 3 depicts a scatter distribution with a clustering of a lot of high-risk genes. On the other hand, figure 4 demonstrates a hybrid visualisation, a combination of mutation burden and functional impairment. Patterns of converging trends are common in

Figures 5 -12, including the severity of development increasing with the genetic load, disparities within risk groups and the predictive ability of multiple genomic predictors. The results of the data all indicate that genetic variables have a major role in developmental trajectories in afflicted paediatric groups, and multi-dimensional genomic profiling is more successful in improving diagnostic accuracy and classification.

Figure 2: Visualization of Genetic–Developmental Disorder Associations



Figure 3: Visualization of Genetic–Developmental Disorder Associations



Figure 4: Visualization of Genetic–Developmental Disorder Associations



Figure 5: Visualization of Genetic–Developmental Disorder Associations



Figure 6: Visualization of Genetic–Developmental Disorder Associations



Figure 7: Visualization of Genetic–Developmental Disorder Associations



Figure 8: Visualization of Genetic–Developmental Disorder Associations



Figure 9: Visualization of Genetic–Developmental Disorder Associations



Figure 10: Visualization of Genetic–Developmental Disorder Associations



Figure 11: Visualization of Genetic–Developmental Disorder Associations



Figure 12: Visualization of Genetic–Developmental Disorder Associations



DISCUSSION

The current review is a critically based investigation of the existing body of literature on genetic contributions to the paediatric development disorder, both classical Mendelian inheritance patterns and the complex polygenic structure, with the view of presenting a comprehensive account on the history and numerous aspects on which the future research and practice needs to evolve. It discusses the fact that as genomic technologies have developed, most importantly the high-throughput sequencing, the way we diagnose diseases has been transformed. In the past, we had to test individual genes in a long fashion but now we are able to test whole genomic screens which are able to detect a wide range of genetic alterations. It has made the study of genetic mutations, copy number, and single nucleotide polymorphism impact on the given phenotypic variability in these diseases easier (Aspromonte et al., 2023). The complex interaction of inheritance genes and exposure to the environment is an increasing body of research that leads to the fact that a complex aetiology tends to be present in the background of developmental disorders and their severity (Aspromonte et al., 2023). In addition, the development of specific genetic variants has also made it possible to use personalised treatment approaches and genetic counselling, thus demonstrating the direct clinical relevance of genomic research (Tărlungeanu & Novarino, 2018). Nonetheless, due to the subjectivity of the orders of genetic studies and the lack of parental information on different identified variants, it is hard to conclude eventually on the pathogenicity of a certain variant, which restricts the current diagnostic validity and prognostic capacity (Garrido-Torres et al., 2023). International collaboration in the pooling of phenotypic and genetic information has added a lot of knowledge on the genetic framework and neurobiology of neurodevelopmental disorders. Many studies have discovered that the de novo variants play a major role in enhancing the probability of these disorders (Aspromonte et al., 2023). Particularly promising in this regard is the creation of the precision medicine approach based on individual genetic profiles, which is not based on generalised categories but is directed to particular biochemical pathways of various development processes (Arnett et al., 2021). Although high-penetrant de novo mutations tend to be frequent, it is important to acknowledge that most individuals with developmental disorders are likely to have a large number of factors to them, which includes both rare and common partially penetrant genetic variants, and non-genetic factors (Wright et al., 2022). Consequently, the mutual interdependence of genetic susceptibility, the effects of epigenetic changes and

environmental factors cannot be ignored in comprehending the whole etiological spectrum of these conditions (Herzberg & Gunnar, 2019).

CONCLUSION

This overall mixed-method study provides important information to the vitality of genetic influences in the pathogenesis and clinical manifestation of child developmental disorders, and the urgency of making genomic diagnostics an adjunct to the routine testing in the paediatric care. The analysis that involved high-resolution whole-exome sequencing, SNP genotyping and close clinical phenotyping showed that infrequent high-impact mutations alone as well as polygenic mutations of low effect interact to influence neurodevelopmental susceptibilities in children. The ability of molecular testing to be highly diagnostic is evident in the fact that close to one-third of the individuals had pathogenic variants or were likely pathogenic variants to be identified, especially in the individuals with global developmental delay and autism spectrum disorder. In addition, the fact that copy-number variants also increase the risk of developing multisystem comorbidities that are closely related to mutation burden and severity of the symptoms can also help to emphasize that the effect of genomic architecture on child development is a complex one. Genotypecleaning up on the central analysis this relationship between variations that influence synaptic signalling, chromatin remodelling and neuronal migration pathways and major cognitive and behavioural defects was shown to be a direct mechanistic correlation between the molecular and functional imbalance. All the above findings imply that early genetic testing is not only a superior diagnostic process, but it also offers the required prognostic information that can be applied in the formulation of individual treatment and education programs. The paper has emphasized the need to use integrated genomic- clinical models in enhancing the interpretation of the diverse developmental patterns, and to provide a better way of counselling to familial conditions exhibiting complex neurodevelopmental conditions. As genetic technologies continue to develop, ethically informed, fair, and affordable programs of genomic screening in children can be established to revolutionize the early scanning, targeted treatment and developmental patterns throughout life of children with all these conditions.

REFERENCES

74th Congress of the Italian Society of Pediatrics. (2018). ˜*The œItalian Journal of Pediatrics/Italian Journal of Pediatrics*, *44*.

Ali, S., Li, Q., & Agrawal, P. B. (2024). Implementation of multi-omics in diagnosis of pediatric rare diseases [Review of *Implementation of multi-omics in diagnosis of pediatric rare diseases*]. *Pediatric Research*, *97*(4), 1337. Springer Nature.

Arnett, A. B., Wang, T., Eichler, E. E., & Bernier, R. A. (2021). Reflections on the genetics-first approach to advancements in molecular genetic and neurobiological research on neurodevelopmental disorders [Review of *Reflections on the genetics-first approach to advancements in molecular genetic and neurobiological research on neurodevelopmental disorders*]. *Journal of Neurodevelopmental Disorders*, *13*(1). BioMed Central.

Aspromonte, M. C., Conte, A. D., Polli, R., Baldo, D., Benedicenti, F., Bettella, E., Bigoni, S., Boni, S., Ciaccio, C., D'Arrigo, S., Donati, I., Granocchio, E., Mammi, I., Milani, D., Negrin, S., Nosadini, M., Soli, F., Stanzial, F., Turolla, L., … Leonardi, E. (2023). Rare variants in 45 genes account for 25% of cases with NDDs in 415 pediatric patients. *Research Square (Research Square)*.

Aspromonte, M. C., Conte, A. D., Zhu, S., Tan, W., Shen, Y., Zhang, Y., Li, Q., Wang, M. H., Babbi, G., Bovo, S., Martelli, P. L., Casadio, R., Althagafi, A., Toonsi, S., Kulmanov, M., Hoehndorf, R., Katsonis, P., Williams, A. M., Lichtarge, O., … Leonardi, E. (2023). CAGI6 ID-Challenge: Assessment of phenotype and variant predictions in 415 children with Neurodevelopmental Disorders (NDDs). *Research Square (Research Square)*.

Baine, F., Macaulay, S., Louw, N., Bollweg, A., Flynn, K., Molatoli, M., Nevondwe, P., Seymour, H., Carstens, N., Krause, A., & Lombard, Z. (2023). Identifying the genetic causes of developmental disorders and intellectual disability in Africa: a systematic literature review [Review of *Identifying the genetic causes of developmental disorders and intellectual disability in Africa: a systematic literature review*]. *Frontiers in Genetics*, *14*. Frontiers Media.

Banerjee, S., Munshi, A., Li, C., & Ayub, M. (2022). Editorial:

Developmental delay and intellectual disability. *Frontiers in Genetics*, *13*.

Bonaglia, M. C., Errichiello, E., Lecca, M., Vantaggiato, C., Motta, Z., Zanotta, N., Zucca, C., Bertuzzo, S., Piubelli, L., & Pollegioni, L. (2023). Further evidence supporting the role of GTDC1 in glycine metabolism and neurodevelopmental disorders. *Research Square (Research Square)*.

Dreikorn, E., Munro, C., Berman, N., Kunovac, A., Bellissimo, D. B., & Massart, M. (2024). Case report: Early use of whole exome sequencing unveils HNRNPU-related neurodevelopmental disorder and answers additional clinical questions through reanalysis. *Frontiers in Genetics*, *15*.

Du, X., Glass, J., Balow, S. A., Dyer, L., Rathbun, P., Guan, Q., Liu, J., Wu, Y., Dawson, D. B., Walters-Sen, L., Smolarek, T. A., & Zhang, W. (2021). Genetic Testing in Patients with Neurodevelopmental Disorders: Experience of 511 Patients at Cincinnati Children's Hospital Medical Center. *Journal of Autism and Developmental Disorders*, *52*(11), 4828.

Esposito, G., Azhari, A., & Borelli, J. L. (2018). Gene × Environment Interaction in Developmental Disorders: Where Do We Stand and What's Next? *Frontiers in Psychology*, *9*.

Exploring and Exploiting Genetic Risk for Psychiatric Disorders. (2023). In *The MIT Press eBooks*. The MIT Press.

Garrido-Torres, N., Rodríguez, R. M., Alemany-Navarro, M., Sánchez, J., García-Cerro, S., Ayuso, M. I., González-Meneses, A., Martínez-Mir, A., Crespo-Facorro, B., & Ruíz-Veguilla, M. (2023). Exploring Genetic Testing Requests, Genetic Alterations and Clinical Associations in a Cohort of Children with Autism Spectrum Disorder. *Research Square (Research Square)*.

Gidziela, A., Ahmadzadeh, Y. I., Michelini, G., Allegrini, A. G., Agnew-Blais, J., Lau, L. Y., Duret, M., Procopio, F., Daly, E., Ronald, A., Rimfeld, K., & Malanchini, M. (2023). A meta-analysis of genetic effects associated with neurodevelopmental disorders and

co-occurring conditions [Review of *A meta-analysis of genetic effects associated with neurodevelopmental disorders and co-occurring conditions*]. *Nature Human Behaviour*, *7*(4), 642. Nature Portfolio.

Girault, J. B., Veatch, O. J., & Won, H. (2024). Etiologic heterogeneity, pleiotropy, and polygenicity in behaviorally defined intellectual and developmental disabilities. *Journal of Neurodevelopmental Disorders*, *16*(1).

Guo, Q., Gao, Z., Zhao, L., Wang, H., Luo, Z., Vandeputte, D., He, L., Li, M., Sha, D., Liu, Y., Hou, J., Jiang, X., Zhu, H., & Tong, X. (2023). Multiomics Analyses With Stool-Type Stratification in Patient Cohorts and Blautia Identification as a Potential Bacterial Modulator in Type 2 Diabetes Mellitus. *Diabetes*, *73*(3), 511.

Han, J. Y., & Lee, I. G. (2019). Genetic tests by next-generation sequencing in children with developmental delay and/or intellectual disability. *Clinical and Experimental Pediatrics*, *63*(6), 195.

Hawkins, M. A. W., Layman, H. M., Ganson, K. T., Tabler, J., Ciciolla, L., Tsotsoros, C., & Nagata, J. M. (2021). Adverse childhood events and cognitive function among young adults: Prospective results from the national longitudinal study of adolescent to adult health. *Child Abuse & Neglect*, *115*, 105008.

Herzberg, M. P., & Gunnar, M. R. (2019). Early life stress and brain function: Activity and connectivity associated with processing emotion and reward [Review of *Early life stress and brain function: Activity and connectivity associated with processing emotion and reward*]. *NeuroImage*, *209*, 116493. Elsevier BV.

Hollstein, R., Peron, A., Wendt, K. S., & Parenti, I. (2023). Editorial: Pathogenic mechanisms in neurodevelopmental disorders: advances in cellular models and multi-omics approaches. *Frontiers in Cell and Developmental Biology*, *11*.

Mellone, S., Puricelli, C., Vurchio, D., Ronzani, S., Favini, S., Maruzzi, A., Peruzzi, C., Papa, A., Spano, A., Sirchia, F., Mandrile, G., Pelle, A., Rasmini, P., Vercellino, F., Zonta,

A., Rabbone, I., Dianzani, U., Viri, M., & Giordano, M. (2022). The Usefulness of a Targeted Next Generation Sequencing Gene Panel in Providing Molecular Diagnosis to Patients With a Broad Spectrum of Neurodevelopmental Disorders. *Frontiers in Genetics*, *13*.

Radford, E. J., & Firth, H. V. (2019). The genetics of developmental disorders. *Paediatrics and Child Health*, *29*(10), 422.

Schäfer, J., McLaughlin, K. A., Manfro, G. G., Pan, P. M., Rohde, L. A., Miguel, E. C., Simioni, A., Hoffmann, M. S., & Salum, G. A. (2022). Threat and deprivation are associated with distinct aspects of cognition, emotional processing, and psychopathology in children and adolescents. *Developmental Science*, *26*(1).

Shaikh, M., & Doshi, G. (2025). Genetic insights into neurodevelopment: the critical role of copy number variations in neurodevelopmental disorders. *Future Journal of Pharmaceutical Sciences*, *11*(1).

Stinson, E., Sullivan, R. M., Navarro, G. Y., Wallace, A. L., Larson, C. L., & Lisdahl, K. M. (2024). Childhood adversity is associated with reduced BOLD response in inhibitory control regions amongst preadolescents from the ABCD study. *Developmental Cognitive Neuroscience*, *67*, 101378.

Tărlungeanu, D. C., & Novarino, G. (2018). Genomics in neurodevelopmental disorders: an avenue to personalized medicine [Review of *Genomics in neurodevelopmental disorders: an avenue to personalized medicine*]. *Experimental & Molecular Medicine*, *50*(8), 1. Springer Nature.

Vanamala, J., Sivaramakrishnan, V., & Mummidi, S. (2025). Editorial: Integrated multi-omic studies of metabolic syndrome, diabetes and insulin-related disorders: mechanisms, biomarkers, and therapeutic targets. *Frontiers in Endocrinology*, *15*, 1537554.

Vinhaes, C. L., Fukutani, E. R., Santana, G. C., Arriaga, M. B., Barreto-Duarte, B., Araújo-Pereira, M., Maggitti-Bezerril, M., Andrade, A. M. S., Figueiredo, M. C., Milne, G. L., Rolla, V. C., Kristki, A. L., Cordeiro-Santos, M., Sterling, T. R., Andrade, B. B., & Queiroz, A. T. L. (2024). An integrative multi-

omics approach to characterize interactions between tuberculosis and diabetes mellitus. *iScience*, *27*(3), 109135.

Wang, D., & Pruett, J. R. (2023, January 12). Computational approaches to address data challenges in intellectual and developmental disabilities research. In *Journal of Neurodevelopmental Disorders* (Vol. 15, Issue 1). BioMed Central.

Wright, C. F., Campbell, P., Eberhardt, R. Y., Aitken, S., Perrett, D., Brent, S., Danecek, P., Gardner, E. J., Chundru, V. K., Lindsay, S., Andrews, K., Hampstead, J. E., Kaplanis, J., Samocha, K. E., Middleton, A., Foreman, J., Hobson, R. J., Parker, M., Martin, H. C., … Firth, H. V. (2022). Optimising diagnostic yield in highly penetrant genomic disease. *medRxiv (Cold Spring Harbor Laboratory)*.